Not your mom’s probiotic: GV-backed Evelo teams up with Mayo Clinic on microbiome drugs
Google Ventures-backed Evelo is joining forces with the Mayo Clinic to develop and eventually commercialize a family of gut bugs as medicine.
You read that right. Evelo’s research is based on the idea that microbes found in the gut can influence biological systems throughout the rest of the body. If true, that means naturally occurring human microbes could potentially be developed as a new class of medicine, the company’s CEO Simba Gill tells me.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
